Heena Sharma Blog

  Zydus Cadila's COVID-19 vaccine ZyCoV-D will initially be used in seven states, including Maharashtra, Tamil Nadu, Uttar Pradesh and West Bengal, which have been recommended to identify the districts with a high number of of beneficiaries who have not received a single dose of a Covid vaccine for its introduction Union Health Secretary Rajesh Bhushan, who reviewed the status and progress of the "Har Ghar Dastak" campaign with the health secretaries and National Health Mission (NHM) directors of the states and Union territories through a video-conference on Thursday, advised the seven states to identify the districts with a high number of first dose left out for the introduction of ZyCoV-D, a statement issued by the health ministry said. The seven states are Bihar, Jharkhand, Maharashtra, Punjab, Tamil Nadu, Uttar Pradesh and West Bengal. ZyCov-D, which is the first COVID-19 vaccine to be cleared by India's drug regulator for those aged 12 years and above, w...

  India's Cadila Healthcare Ltd has sought approval from local regulators to use a Hepatitis C drug as a treatment for COVID-19 following promising interim results from a late-stage trial, the drug maker said on Monday. A single dose of the Hepatitis C drug when taken early could help COVID-19 patients recover faster and avoid complications seen in the advanced stages of the disease, Cadila said in a statement to stock exchanges. About 91% of patients treated with the drug tested negative for COVID-19 in standard RT-PCR tests by day seven, compared to nearly 79% who were given the standard of care, the company said citing Phase-III clinical trial data. The drug, known as Pegylated Interferon alpha-2b and branded as 'PegiHep' by Cadila, was originally approved for liver disease Hepatitis C and launched in India 10 years ago. It is being repurposed to treat COVID-19. Read More